Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Journal of the Society for Gynecologic Investigation
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gabriel, B.
Right arrow Articles by Hasenburg, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gabriel, B.
Right arrow Articles by Fischer, D.-C
Right arrow Articles by Orlowska-Volk, M.
Right arrow Articles by zur Hausen, A.
Right arrow Articles by Schüle, R.
Right arrow Articles by Müller, J. M.
Right arrow Articles by Hasenburg, A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Breast Cancer
Hazardous Substances DB
*TAMOXIFEN
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Expression of the Transcriptional Coregulator FHL2 in Human Breast Cancer: A Clinicopathologic Study

Boris Gabriel, MD

Department of Obstetrics and Gynecology and Molecular Gynecology, Center for Clinical Research, and Department of Pathology, Freiburg University Medical Center, Freiburg, Germany; Department of Obstetrics and Gynecology, Heidelberg University Medical Center, Heidelberg, Germany bGabriel{at}frk.ukl.uni-freiburg.de

Dagmar-C Fischer, PhD

M. Orlowska-Volk, MD

Axel zur Hausen, MD

Roland Schüle, PhD

Judith M. Müller, PhD

Annettee Hasenburg, MD

Department of Obstetrics and Gynecology and Molecular Gynecology, Center for Clinical Research, and Department of Pathology, Freiburg University Medical Center, Freiburg, Germany; Department of Obstetrics and Gynecology, Heidelberg University Medical Center, Heidelberg, Germany

Objective: Although the Four and a Half LIM domain protein 2 (FHL2) has been suggested to play an important role in tumor development, this has not been investigated in breast cancer.

Methods: Paraffin-embedded tissues from patients (n = 85) with primary breast cancer were submitted to immunohistochemical investigation of FHL2 expression and subsequent correlation with clinicopathologic parameters and patient survival.

Results: The expression of FHL2 was confined to the cytoplasm of the tumor cells. Forty (47%) of 85 samples showed weake expression of FHL2, whereas high expression was found in 45 tumors (53%). A statistically significant positive correlation was observed between FHL2 and androgen receptor expression (P = .029). Patients with tumors expressing low amounts of FHL2 were characterized by a significantly better survival compared to those with high intratumoral FHL2 expression (P = .0215, log-rank test). The additional stratification according to adjuvant tamoxifen treatment revealed a significantly improved survival rate for patients receiving tamoxifen and being diagnosed with a tumor expressing high amounts of FHL2. This might indicate that tamoxifen is at least partially capable of reversing the negative prognostic impact of high FHL2 expression. Multivariate Cox regression analysis revealed FHL2 expression as a significant indepenent predictor of survival.

Conclusion: The specific in tumor tissue points to an important functional role of FHL2 in human breast cancer. Our survival data indicate that the expression of FHL2 in primary breast cancer is a potentially relevant prognostic factor. Further studies are warranted to elucidate whether analysis of FHL2 expression is suitable to predict response to antihormonal treatment with tamoxifen.

Key Words: FHL2 • breast cancer • prognostic marker • survival

References

Journal of the Society for Gynecologic Investigation, Vol. 13, No. 1, 69-75 (2006)
DOI: 10.1016/j.jsgi.2005.10.001
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gabriel, B.
Right arrow Articles by Hasenburg, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gabriel, B.
Right arrow Articles by Fischer, D.-C
Right arrow Articles by Orlowska-Volk, M.
Right arrow Articles by zur Hausen, A.
Right arrow Articles by Schüle, R.
Right arrow Articles by Müller, J. M.
Right arrow Articles by Hasenburg, A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Breast Cancer
Hazardous Substances DB
*TAMOXIFEN
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?